Accenture has launched a new business service, known as Accelerated R&D Services, to accelerate drug development from discovery to approval to market.
Subscribe to our email newsletter
Focused on delivering streamlined and integrated research and development (R&D) functions, the service will help pharmaceutical companies bring new medications to patients at a faster pace.
The company has planned to invest over $200m in delivering this service which results in driving efficient and effective development of pharmaceutical products for clients.
The company’s R&D services will use all the capabilities of cloud, mobility and analytics to deliver integrated functions and market launch predicated on delivering better patient outcomes.
Accelerated R&D Services helps life sciences companies bring drugs to market faster, at less cost and with reduced execution risks using a pay-for-performance business model for business process outsourcing.
To support the strategic R&D initiatives, the company is operating with a leading pharmaceutical company to build a clinical data aggregation and exchange platform.
The company is also currently working with associations such as CDISC and Transcelerate BioPharma to advance industry-wide clinical data standards, streamline research processes and encourage the discovery of new medicines for patients by pharmaceutical and biotechnology research companies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.